ruxolitinib
Showing 51 - 75 of 345
Chronic Myelomonocytic Leukemia, Leukemia Trial in United States (Ruxolitinib)
Active, not recruiting
- Chronic Myelomonocytic Leukemia
- Leukemia
- Ruxolitinib
-
Tampa, Florida
- +4 more
Nov 11, 2022
Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, MDS Trial in Minneapolis, Saint Louis, Rochester (Decitabine,
Completed
- Acute Myeloid Leukemia
- +2 more
- Decitabine
- +2 more
-
Minneapolis, Minnesota
- +2 more
Nov 2, 2022
Acute Lymphoblastic Leukemia Trial in New York (Ruxolitinib, Dasatinib, Dexamethasone)
Active, not recruiting
- Acute Lymphoblastic Leukemia
- Ruxolitinib
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 25, 2022
Hemophagocytic Lymphohistiocytosis Trial in United States (Ruxolitinib, Dexamethasone, Etoposide)
Recruiting
- Hemophagocytic Lymphohistiocytosis
- Ruxolitinib
- +2 more
-
Phoenix, Arizona
- +9 more
Jan 9, 2023
Myelofibrosis Trial in Hong Kong (Bomedemstat)
Recruiting
- Myelofibrosis
-
Hong Kong, Hong KongDepartment of Medicine, the University of Hong Kong, Queen Mary
Oct 3, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation Trial in United States
Recruiting
- Acute Myeloid Leukemia
- +2 more
- Ruxolitinib
-
Boston, Massachusetts
- +5 more
Oct 21, 2022
Necrobiosis Lipoidica Trial in Scottsdale (Ruxolitinib)
Completed
- Necrobiosis Lipoidica
- Ruxolitinib
-
Scottsdale, ArizonaMayo Clinic in Arizona
Mar 17, 2022
Metastatic Malignant Tumor in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma Trial in
Active, not recruiting
- Metastatic Malignant Neoplasm in the Bone
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Scottsdale, ArizonaMayo Clinic in Arizona
Jan 4, 2023
Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia,
Recruiting
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- +3 more
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Ruxolitinib for Polycythemia Vera in Patients Resistant to or
Completed
- Polycythemia Vera (PV)
- Ruxolitinib
-
East Hanover, New JerseyNovartis Investigative Site
Jun 29, 2022
Cutaneous Lichen Planus Trial in Canada, United States (Ruxolitinib cream, Vehicle cream)
Recruiting
- Cutaneous Lichen Planus
- Ruxolitinib cream
- Vehicle cream
-
Birmingham, Alabama
- +6 more
Dec 1, 2022
Advanced Cutaneous Squamous Cell Carcinoma Trial in Atlanta, Chicago, New York (Ruxolitinib)
Recruiting
- Advanced Cutaneous Squamous Cell Carcinoma
- Ruxolitinib
-
Atlanta, Georgia
- +2 more
Jun 28, 2022
Myelofibrosis Trial in United States (Ruxolitinib, Thalidomide)
Active, not recruiting
- Myelofibrosis
- Ruxolitinib
- Thalidomide
-
Middletown, New Jersey
- +6 more
Aug 23, 2022
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata Trial run by the National Institute of
Recruiting
- Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)
- Alopecia Areata
- Ruxolitinib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Polycythemia Vera Trial (Ruxolitinib)
Available
- Polycythemia Vera
- Ruxolitinib
- (no location specified)
Mar 7, 2022
Macrophage Activation Syndrome Trial (Ruxolitinib, methylprednisolone)
Not yet recruiting
- Macrophage Activation Syndrome
- Ruxolitinib
- methylprednisolone
- (no location specified)
Mar 16, 2022
Coronavirus Infection Trial in Madrid (Ruxolitinib plus simvastatin, Standard of Care)
Completed
- Coronavirus Infection
- Ruxolitinib plus simvastatin
- Standard of Care
-
Madrid, SpainHospital Universitario Madrid Sanchinarro
Jun 3, 2022
aGVHD, Stem Cell Transplant Complications Trial in Beijing (Ruxolitinib 10 mg twice a day combined with Corticosteroids,
Completed
- aGVHD
- Stem Cell Transplant Complications
- Ruxolitinib 10 mg twice a day combined with Corticosteroids
- +3 more
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Dec 12, 2021
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells,
Completed
- Blasts More Than 20 Percent of Bone Marrow Nucleated Cells
- +4 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Lymphoma Trial in United States (Ruxolitinib)
Recruiting
- Lymphoma
- Ruxolitinib
-
Miami, Florida
- +9 more
Oct 5, 2022
Kohlmeier Degos Disease With Neurologic Involvement Trial run by the National Heart, Lung, and Blood Institute (NHLBI)
Recruiting
- Kohlmeier Degos Disease With Neurologic Involvement
- Ruxolitinib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 23, 2023
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute
Active, not recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +2 more
- Ruxolitinib
- Venetoclax
-
Columbus, Ohio
- +2 more
Aug 10, 2022
Myelofibrosis, Polycythemia Vera Trial in United States (TGR-1202, ruxolitinib)
Active, not recruiting
- Myelofibrosis
- Polycythemia Vera
- TGR-1202
- ruxolitinib
-
Phoenix, Arizona
- +4 more
Jun 20, 2022